{
    "clinical_study": {
        "@rank": "46737", 
        "arm_group": {
            "arm_group_label": "MT-1303", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and\n      pharmacodynamics of a single oral dose of MT-1303 in subjects with inflammatory bowel\n      disease."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Inflammatory Bowel Disease", 
        "condition_browse": {
            "mesh_term": [
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, non-randomised, single-dose study to evaluate the safety,\n      tolerability, pharmacokinetics and pharmacodynamics of MT-1303 in subjects with inflammatory\n      bowel disease (Crohn's Disease and Ulcerative Colitis)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A body mass index (BMI) ranging from 16 to 34 kg/m2\n\n          -  Subjects who were diagnosed as Crohn's Disease or Ulcerative Colitis at least 6\n             months prior to Screening, clinically confirmed either by radiological, endoscopic or\n             histological examination.\n\n          -  Subjects who have had at least one flare within 18 months prior to Screening.\n\n          -  Confirmed medical records of inflammatory lesions in intestinal tract\n\n        Exclusion Criteria:\n\n          -  Present or past history of clinically significant gastrointestinal surgery.\n\n          -  Present or past history of clinically significant stenosis, stricture or fistula in\n             small intestine or colon.\n\n          -  Known hypersensitivity to any formulation excipients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666327", 
            "org_study_id": "MT-1303-E03"
        }, 
        "intervention": {
            "arm_group_label": "MT-1303", 
            "intervention_name": "MT-1303", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Crohn's Disease", 
            "Ulcerative Colitis"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacodynamics of a Single Oral Dose of MT-1303 in Subjects With Inflammatory Bowel Disease.", 
        "overall_contact": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials INformation Desk"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability of single dose of MT-1303 assessed by number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1month"
            }, 
            {
                "measure": "Peak plasma concentration (Cmax) of MT-1303 and its metabolite", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to 1 month"
            }, 
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of MT-1303 and its metabolite", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to 1 month"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666327"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamic effect of MT-1303 on lymphocyte count", 
                "safety_issue": "No", 
                "time_frame": "16 time points up to 1 month"
            }, 
            {
                "measure": "Exploratory parameter : C-reactive protein (CRP)", 
                "safety_issue": "No", 
                "time_frame": "4 time points up to 1 week"
            }, 
            {
                "measure": "Exploratory parameter :Erythrocyte sedimentation (ESR)", 
                "safety_issue": "No", 
                "time_frame": "4 time points up to 1 week"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}